Inflammation/coagulopathy/fibrinolysis: Dynamic indicators of COVID-19 progression in patients with moderate COVID-19 in Wenzhou, China

被引:3
|
作者
An, Hui [1 ,2 ]
Zhang, Jitai [1 ]
Zhou, Tong [1 ,3 ]
Li, Ting [2 ]
Li, Shan [1 ]
Huang, Caili [1 ]
Chen, Chengshui [4 ]
Ying, Binyu [5 ]
Xu, Zhangye [3 ]
Jin, Shengwei [1 ,2 ]
Li, Xiaokun [6 ]
Li, Ming [1 ]
机构
[1] Wenzhou Med Univ, Sch Basic Med Sci, Wenzhou, Peoples R China
[2] Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Dept Anesthesia & Crit Care, Wenzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Affiliated Hosp 2, Dept Gynecol & Obstet, Wenzhou, Peoples R China
[4] Wenzhou Med Univ, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Wenzhou, Zhejiang, Peoples R China
[5] Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Dept Crit Care Med, Wenzhou, Zhejiang, Peoples R China
[6] Wenzhou Med Univ, Sch Pharm, Wenzhou, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Coronavirus disease 2019; Coagulopathy; Fibrinolysis; C-reactive protein; D-dimer; COAGULATION;
D O I
10.1016/j.clim.2021.108852
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The majority of the coronavirus disease 2019 (COVID-19) non-survivors meet the criteria for disseminated intravascular coagulation (DIC). Although timely monitoring of clotting hemorrhagic development during the natural course of COVID-19 is critical for understanding pathogenesis, diagnosis, and treatment of the disease, however, limited data are available on the dynamic processes of inflammation/coagulopathy/fibrinolysis (ICF). Methods: We monitored the dynamic progression of ICF in patients with moderate COVID-19. Out of 694 COVID19 inpatients from 10 hospitals in Wenzhou, China, we selected 293 adult patients without comorbidities. These patients were divided into different daily cohorts according to the COVID-19 onset-time. Furthermore, data of 223 COVID-19 patients with comorbidities and 22 critical cases were analyzed. Retrospective data were extracted from electronic medical records. Results: The virus-induced damages to pre-hospitalization patients triggered two ICF fluctuations during the 14day course of the disease. C-reactive protein (CRP), fibrinogen, and D-dimer levels increased and peaked at day 5 (D) 5 and D9 during the 1st and 2nd fluctuations, respectively. The ICF activities were higher during the 2nd fluctuation. Although 12-day medication returned high CRP concentrations to normal and blocked fibrinogen increase, the D-dimer levels remained high on days 17 +/- 2 and 23 +/- 2 days of the COVID-19 course. Notably, although the oxygenation index, prothrombin time and activated partial thromboplastin time were within the normal range in critical COVID-19 patients at administration, 86% of these patients had a D-dimer level > 500 mu g/L. Conclusion: COVID-19 is linked with chronic DIC, which could be responsible for the progression of the disease. Understanding and monitoring ICF progression during COVID-19 can help clinicians in identifying the stage of the disease quickly and accurately and administering suitable treatment.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Outbreak of COVID-19 in a family, Wenzhou, China
    Zhou, Zu-Mu
    Zhou, Hai-Zhen
    Lin, Xian-Dan
    SU, Zhi-Cheng
    Zhao, Lu-Shuang
    Chen, Xi
    [J]. EPIDEMIOLOGY AND INFECTION, 2020, 148
  • [2] Coagulopathy and COVID-19
    Lorini, Ferdinando Luca
    Di Matteo, Maria
    Gritti, Paolo
    Grazioli, Lorenzo
    Benigni, Alberto
    Zacchetti, Lucia
    Bianchi, Isabella
    Fabretti, Fabrizio
    Longhi, Luca
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0E) : E95 - E98
  • [3] Coagulopathy and COVID-19
    Yazici, Onur
    Bozkus, Fulsen
    Demirci, Nilgun
    Gulhan, Pinar Yildiz
    Coskun, Funda
    [J]. EURASIAN JOURNAL OF PULMONOLOGY, 2020, 22 (04) : 67 - 69
  • [4] Coagulopathy in COVID-19
    Iba, Toshiaki
    Levy, Jerrold H.
    Levi, Marcel
    Thachil, Jecko
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (09) : 2103 - 2109
  • [5] COVID-19 and coagulopathy
    Sarkar, Malay
    Madabhavi, Irappa, V
    Pham Nguyen Quy
    Govindagoudar, Manjunath B.
    [J]. CLINICAL RESPIRATORY JOURNAL, 2021, 15 (12): : 1259 - 1274
  • [6] Coagulopathy and COVID-19
    Ploplis, Victoria A.
    [J]. CURRENT DRUG TARGETS, 2022, 23 (17) : 1537 - 1538
  • [7] COVID-19 Coagulopathy
    Rettew, Andrew
    Garrahy, Ian
    Rahimian, Shoja
    Brown, Rebecca
    Sangha, Navdeep
    [J]. LIFE-BASEL, 2024, 14 (08):
  • [8] Coagulopathy in COVID-19
    Lio, Ka U.
    Rali, Parth
    [J]. LUNG INDIA, 2021, 38 (07) : S53 - S57
  • [9] COVID-19 coagulopathy
    Katyal, Anup
    [J]. CLEVELAND CLINIC JOURNAL OF MEDICINE, 2020, 87 (12) : 712 - 712
  • [10] Fibrinolysis and Inflammation in Convalescent Plasma Treated COVID-19 Patients
    Yao, B.
    Sarva, K.
    Florova, G.
    Hibbard, R.
    Devine, M.
    Philley, J.
    Idell, S.
    McPherson, D. D.
    Komissarov, A. A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207